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Abstracts / International Journal of Surgery 12 (2014) S13eS117S16Methods: Clinical data and MMP-3 levels were recorded prospectively for
278 RA patients over a 5-year period. The mean (sd) age of the cohort was
59 (9.9) years with a disease duration of 11(9.2) years and 187 (67%) of the
cohort were female.
Results: Signiﬁcantly higher levels of MMP-3 were found at baseline for
those patients who required a joint replacement during the ﬁve year
follow up period (n¼49) than those that did not: median (IQR) MMP-3
level (27,050 (37,146) vs. 19,892 (18,894), p ¼0.005). No signiﬁcant differ-
ence was found between baseline MMP-3 levels and having a joint
replacement prior to the start of the study (n¼32): median (IQR) MMP-3
level (25,705 (21,283) vs. 20,031 (20,258), p ¼0.25).
Conclusions: High levels of MMP-3 are associated with future joint
replacement of the hip or knee in RA patients.
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Introduction: Phospholipase Cg-1 (PLCg-1) is an important Hepatocyte
Growth Factor (HGF) receptor (C-MET) downstream mediator, and recent
evidence showed that Suppressor of Cytokine Signalling 7(SOCS7) - a
member of the SOCS family - interacts with PLCg-1. Here, we aimed to
investigate SOCS7 knockdown effect on breast cancer cellular growth and
migratory responses to HGF treatment, and whether this involves HGF-
PLCg-1 pathway using the PLCg-1 blocker U73122.
Methods: Two breast cancer cell lines (MCF7 and MDA-MB-231) were
transfected with anti-SOCS7 ribozymal transgene, creating sublines
with SOCS7 knockdown (MCF7DSOCS7 and MDA-MB-231DSOCS7), veriﬁed
by RT-PCR. The growth and migration of the cells were evaluated with
and without HGF and U73122 pre-treatment using growth assay,
scratch-wound and Electrical Cell Impedance Sensing (ECIS) migration
assays.
Results: Under basic conditions, both MCF7DSOCS7 and MDA-MB-231DSOCS7
cells showed higher growth and migration compared to control cells.
Additionally SOCS7 knockdown appeared to synergistically enhance their
growth and migratory responses to HGF. U73122 pre-treatment was found
to abrogate this synergistic effect.
Conclusions: HGF pre-treatment and SOCS7 knockdown have a syner-
gistic effect on the growth and migration of MCF7 and MDA-MB-231 cells.
This is lost with pre-treatment with U73122, an alternative PLCg-1 blocker,
indicating a precise anti-PLCg-1 regulatory role for SOCS7.
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Introduction: There is growing interest in the potential of autologous
fat grafting (AFG) for breast reconstruction. However, concerns
remains regarding its effectiveness, safety and interference with
mammography.
Methods: A protocol was published a priori. All studies investigating AFG
for women undergoing reconstruction post surgery for treatment of breast
cancer were considered. We assessed six domains; Oncological, clinical,
aesthetic/functional, patient reported, process and radiological. Electronic
databases and grey literature sources were searched to June 2013.
Results: 31 studies were included in this review (3,521 patients). Fat ne-
crosis is the commonest reported complication at 4.4% (the majority was
managed conservatively). Other harms include the anxiety caused by the
need for further radiological investigation through interval mammograms
(11.5%) and the need for biopsy (2.5%) to exclude malignancy. Theweighted mean recurrence rate was 4.4% at a median of 18.3 months.
Random effects Meta-analysis showed no signiﬁcant difference (p¼0.10).
We were unable to comment from the data on whether AFG is more
successful in combination with other techniques or alone.
Conclusions: The need for long-term follow up is underscored by this
review. High quality research is required to demonstrate long-term
oncological ramiﬁcations and to determine the potential for AFG as a total
breast reconstruction.
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Introduction: Neoadjuvant therapy (NAT) offers an opportunity to
assess tumour response to systemic agents. However discrepancy may
exist between response of primary tumour & involved nodes. This
study sought to assess the frequency of discordance in this response post
NAT.
Methods: All node positive patients receiving NAT at Cork University
Hospital, Republic of Ireland from 2009-2012 were identiﬁed. Basic
demographics, radiological & pathological features were tabulated &
analysed. Nodal response was estimated from standard pathological
response to treatment measurements. Statistical analysis was performed.
Results: 66 node positive patients had completed surgery & were eligible
for inclusion. Median age was 50 years, all patients underwent axillary
clearance and 64% underwent mastectomy. There was an overall positive
correlation between tumour and lymph node (LN) response following NAT
(Spearman correlation coefﬁcient 0.541, p<0.001). Eleven patients ach-
ieved a LN complete pathological response (CPR) with all having a CPR in
tumour also. A CPR in the tumour predicted complete nodal response in
73% of cases.
Conclusions:While overall correlation was seen, 27% of primary tumours
with CPR had persistently positive LN's. This represents a signiﬁcant
discordance that may be due to biomolecular differences and represents a
concern for the potential lack of response of occult systemic metastasis to
NAT.
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Introduction: To investigate whether medical professionals, when con-
fronted with a breast cancer diagnosis, would ignore evidence-based
medicine in favour of personal preference. Compare the opinion of the
breast team with the actual treatment chosen by their patients.
Methods: Anonymous questionnaire with 3 scenarios given to all (39)
members of the regional MDT and comparison made with patients'
treatment choices.
Results: For a 10 mm, grade 1 cancer 82 % (32/39) of health professionals
favoured WLE over mastectomy, compared to 51 % (31/60) of patients
(p¼0.003). For a 25mm, grade II, invasive cancer 55% (21/38) of medical
professionals favoured WLE compared to 49% (28/57) of patients
(p¼0.67). For 60mm, high grade DCIS, 26% (10/39) of health professionals
would chose mastectomy without reconstruction, compared to 75 % (9/
12) of patients (p¼0.005). Following a mastectomy, 74 % of health pro-
fessionals would have reconstruction: 28 % immediately, 46 % delayed;
whilst of the 25 % of patients with reconstructions all had immediate
reconstruction.
Conclusions: A signiﬁcant majority of health professionals would
choose WLE for grade I and II invasive ductal carcinoma compared to
their patients' treatment choices. For 60mm DCIS, health professionals
were more three times more likely than their patients to choose re-
construction.
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